TY - JOUR
T1 - CNS-targeting pharmacological interventions for the metabolic syndrome
AU - Stemmer, Kerstin
AU - Müller, Timo D.
AU - DiMarchi, Richard D.
AU - Pfluger, Paul T.
AU - Tschöp, Matthias H.
N1 - Publisher Copyright:
© 2019, American Society for Clinical Investigation.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
AB - The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
UR - http://www.scopus.com/inward/record.url?scp=85071171615&partnerID=8YFLogxK
U2 - 10.1172/JCI129195
DO - 10.1172/JCI129195
M3 - Review article
C2 - 31380808
AN - SCOPUS:85071171615
SN - 0021-9738
VL - 129
SP - 4058
EP - 4071
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -